Live Breaking News & Updates on நிறுவனம் ப்ரோடீந் அறிவியல்

Stay updated with breaking news from நிறுவனம் ப்ரோடீந் அறிவியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Bio-Techne Releases Fourth Quarter Fiscal 2021 Results

Bio-Techne Releases Fourth Quarter Fiscal 2021 Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Chuck Kummeth , David Clair , Exchange Commission , Company Diagnostics , Protein Sciences , Company Protein Sciences , Protein Sciences Segment , Investor Relations Corporate Development , Bio Techne Corporation , Operating Margin , Financial Measures , Gene Therapies , Quarter Fiscal , Year Fiscal , Looking Statements , Private Securities Litigation Reform , Techne Corporation , Senior Director , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , டேவிட் கிளேர் , பரிமாற்றம் தரகு , நிறுவனம் பரிசோதனை , ப்ரோடீந் அறிவியல் , நிறுவனம் ப்ரோடீந் அறிவியல் ,

Bio-Techne Releases Fourth Quarter Fiscal 2021 Results

Bio-Techne Releases Fourth Quarter Fiscal 2021 Results
mesabitribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mesabitribune.com Daily Mail and Mail on Sunday newspapers.

United States , Chuck Kummeth , David Clair , Exchange Commission , Company Diagnostics , Protein Sciences , Company Protein Sciences , Protein Sciences Segment , Investor Relations Corporate Development , Bio Techne Corporation , Operating Margin , Financial Measures , Gene Therapies , Quarter Fiscal , Year Fiscal , Looking Statements , Private Securities Litigation Reform , Techne Corporation , Senior Director , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , டேவிட் கிளேர் , பரிமாற்றம் தரகு , நிறுவனம் பரிசோதனை , ப்ரோடீந் அறிவியல் , நிறுவனம் ப்ரோடீந் அறிவியல் ,

Bio-Techne Releases Third Quarter Fiscal 2021 Results

Share this article
Share this article
MINNEAPOLIS, May 6, 2021 /PRNewswire/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2021.
Third Quarter FY2021 Snapshot
Third quarter organic revenue increased by 22% (25% reported) to $243.6 million and 17% (19% reported) in the first nine months of fiscal 2021 to $672.0 million.
GAAP EPS was $1.12 versus $0.92 one year ago. Delivered adjusted earnings per share (EPS) of $1.79 versus $1.39 one year ago.
Adjusted Operating Margin increased to 40.1% in the third quarter of fiscal 2021 compared to 36.4% in the third quarter of fiscal 2020.
Excellent commercial execution in both operating segments with Protein Sciences achieving record organic growth of 24% and Diagnostics and Genomics delivering 17% organic growth. ....

United States , Chuck Kummeth , David Clair , Company Diagnostics , Company Protein Sciences , Asuragen Inc , Bio Techne Corporation , Exchange Commission , Protein Sciences , Protein Sciences Segment , Investor Relations Corporate Development , Operating Margin , Financial Measures , Gene Therapy , Quarter Fiscal , Looking Statements , Private Securities Litigation Reform , Techne Corporation , Senior Director , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , டேவிட் கிளேர் , நிறுவனம் பரிசோதனை , நிறுவனம் ப்ரோடீந் அறிவியல் , உயிர் தொழில்நுட்பம் நிறுவனம் , பரிமாற்றம் தரகு ,

Bio-Techne Releases Second Quarter Fiscal 2021 Results

Share this article
Share this article
MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2020.
Second Quarter FY2021 Snapshot
Second quarter organic revenue increased by 19% (21% reported) to $224.3 million and 15% (16% reported) in the first half of fiscal 2021 to $428.5 million.
GAAP EPS was $1.15 versus $3.02 one year ago primarily relating to a non-recurring gain of approximately $121 million in our ChemoCentryx investment in the second quarter of fiscal 2020. Delivered record adjusted earnings per share (EPS) of $1.62 versus $1.08 one year ago.
Adjusted Operating Margin increased to 38.7% in the second quarter of fiscal 2021 compared to 33.4% in the second quarter of fiscal 2020. ....

United States , Chuck Kummeth , David Clair , Exchange Commission , Company Diagnostics , Protein Sciences , Company Protein Sciences , Protein Sciences Segment , Investor Relations Corporate Development , Bio Techne Corporation , Operating Margin , Financial Measures , Chief Executive Officer , Gene Therapy , Quarter Fiscal , Looking Statements , Private Securities Litigation Reform , Techne Corporation , Senior Director , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , டேவிட் கிளேர் , பரிமாற்றம் தரகு , நிறுவனம் பரிசோதனை , ப்ரோடீந் அறிவியல் , நிறுவனம் ப்ரோடீந் அறிவியல் ,